Analysts Offer Insights on Healthcare Companies: pSivida (NASDAQ: PSDV) and Aimmune Therapeutics (NASDAQ: AIMT)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on pSivida (NASDAQ: PSDV) and Aimmune Therapeutics (NASDAQ: AIMT) with bullish sentiments.

pSivida (NASDAQ: PSDV)

In a report released yesterday, Vernon Bernardino from FBR Capital reiterated a Buy rating on pSivida (NASDAQ: PSDV). The company’s shares opened today at $1.75, close to its 52-week low of $1.50.

According to TipRanks.com, Bernardino is ranked 0 out of 5 stars with an average return of -10.8% and a 27.7% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Actinium Pharmaceuticals, and Conatus Pharmaceuticals.

Currently, the analyst consensus on pSivida is Strong Buy and the average price target is $10.17, representing a 481.1% upside.

In a report issued on May 30, H.C. Wainwright also reiterated a Buy rating on the stock with a $8 price target.
Aimmune Therapeutics (NASDAQ: AIMT)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Aimmune Therapeutics (NASDAQ: AIMT) today. The company’s shares opened today at $18.43.

Moussatos noted:

“Updosing phase completed in PALISADE—topline results in early 2018. Aimmune reported that almost (97%) all of the 554 enrolled 4-49yo peanut-allergic Phase 3 PALISADE patients have completed the updosing phase which starts the 6 month countdown to topline pivotal data release (early Q1:18). Aimmune stated that powering is above initial expectations. At this point, we believe no additional news, such as amendments to the safety protocol, is a likely signal for trial success.”

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.3% and a 44.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Catabasis Pharmaceuticals, and miRagen Therapeutics Inc.

Aimmune Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $38.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.